Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2018
At a glance
- Drugs NS 065 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors NS Pharma
- 29 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 16 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2018.